Table of Content


Introduction
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Development
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics Assessment
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies Involved in Therapeutics Development
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products
5’ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Akeso Inc, H1 2020
Pipeline by Aprilbio Co Ltd, H1 2020
Pipeline by Arcus Biosciences Inc, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Aurigene Discovery Technologies Ltd, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Calithera Biosciences Inc, H1 2020
Pipeline by Corvus Pharmaceuticals Inc, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by Eternity Bioscience Inc, H1 2020
Pipeline by Evotec SE, H1 2020
Pipeline by Gilead Sciences Inc, H1 2020
Pipeline by Harbour BioMed, H1 2020
Pipeline by I-Mab Biopharma Co Ltd, H1 2020
Pipeline by Innate Pharma SA, H1 2020
Pipeline by InteRNA Technologies BV, H1 2020
Pipeline by iOnctura SA, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Novartis AG, H1 2020
Pipeline by ORIC Pharmaceuticals Inc, H1 2020
Pipeline by Phanes Therapeutics Inc, H1 2020
Pipeline by Secarna Pharmaceuticals GmbH & Co. KG, H1 2020
Pipeline by Shanghai De Novo Pharmatech Co Ltd, H1 2020
Pipeline by Shanghai Henlius Biotech Inc, H1 2020
Pipeline by Xcella Biosciences Inc, H1 2020
Dormant Projects, H1 2020